Atorvastatin and the ability of clopidogrel to inhibit platelet aggregation.
Shechter
Michael
M
D000069059:Atorvastatin; D000077144:Clopidogrel; D004305:Dose-Response Relationship, Drug; D006083:Graft Occlusion, Vascular / Q000517:prevention & control; D006538:Heptanoic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D015539:Platelet Activation / Q000187:drug effects; D010973:Platelet Adhesiveness / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors* / Q000627:therapeutic use
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin; D000077144:Clopidogrel; D013988:Ticlopidine